Search Results

Nutcracker Therapeutics, Inc., a biotechnology company dedicated to developing transformative RNA therapies through its proprietary technology platform, detailed data presented by its partners at the University of California, San Francisco on foundational prostate cancer antigen research utilized to inform the development of its mRNA drug candidate, NTX-470.

Dyadic International, Inc. today announced that Joseph Hazelton, Chief Business Officer and Doug Pace, Executive Vice President of Business Development will be attending the Future Food-Tech “Innovation & Investment from Farm to Fork” event March 21 – 22, 2024 at the San Francisco Marriott Marquis in California.

Genentech’s latest layoffs are the second round of workforce reductions this year, following the company’s announcement in April that it was letting go around 3% of employees.

Astellas Pharma Inc. announced the opening of a new $90 million, state-of-the-art center at 480 Forbes Boulevard in South San Francisco, CA.

FibroGen expects its headcount reduction, which is tied to eliminating 75% of its U.S. workforce, to be mostly complete by the end of the first quarter of 2025.

OSE Immunotherapeutics SA, presented a poster on preclinical data on its mRNA therapeutic platform for the treatment of inflammatory and autoimmune disorders at the Federation of Clinical Immunology Societies annual meeting held in San Francisco.

The San Francisco Business Times has named Gladstone Institutes President Deepak Srivastava, MD, as one of the Most Admired CEOs among Bay Area businesses and nonprofits.

Acasti Pharma Inc. today announced that Chief Executive Officer Prashant Kohli will participate in the following investor and industry networking events in San Francisco, California during the week of January 7-12, 2024.